Otsuka Pharmaceutical Co., Ltd. (OPC), held by Tokyo-listed Otsuka Holdings, is acquiring venture-funded Neurovance, Inc. (Neurovance) a privately held, clinical-stage pharmaceutical company focused on attention-deficit hyperactivity disorder (ADHD) and related disorders.
Start your deal-making journey now!
Subscribe now to enjoy unlimited access at just $59.
Premium coverage on private equity, venture capital, and startups in Asia.
Exclusive scoops from our reporters in nine key markets.
In-depth interviews with industry leaders shaping the ecosystem.
Already a Subscriber? Log in
Contact us for corporate subscriptions at subs@dealstreetasia.com
